Identifying tumour-associated antigens

Antibody-directed enzyme prodrug therapy (ADEPT) is a recent development for a selective treatment of cancer, based on site-directed formation at the surface of malignant cells of cytotoxic compounds from non-toxic prodrugs with a conjugate of an appropriate enzyme and a monoclonal antibody which binds to tumour-associated antigens. New potent prodrugs of analogues of the antibiotic CC-1065 have been developed. These show a remarkable selectivity with a Q(IC50) value of up to more than 3000. Moreover, the formed drug has a high potency with an IC50 of 30 pM.

Download Full-text

Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma

European Journal of Cancer and Clinical Oncology ◽

10.1016/0277-5379(89)90310-6 ◽

1989 ◽

Vol 25 (11) ◽

pp. 1637-1643 ◽

Cited By ~ 9

Author(s):

Anna K. Ghosh ◽

Thomas Cerny ◽

John Wagstaff ◽

Nicholas Thatcher ◽

Michael Moore

Keyword(s):

Metastatic Melanoma ◽

Interferon Gamma ◽

Tumour Associated Antigens ◽

In Vivo Administration

Download Full-text

Tumour-Associated Antigens for Cystadenocarcinoma of the Ovary

Clinics in Obstetrics and Gynaecology ◽

10.1016/s0306-3356(21)00562-8 ◽

1983 ◽

Vol 10 (2) ◽

pp. 187-196

Author(s):

Joseph J. Barlow ◽

Malaya Bhattacharya

Keyword(s):

Tumour Associated Antigens

Download Full-text

Cancer Immunotherapy in Children

Oxford Textbook of Cancer in Children ◽

10.1093/med/9780198797210.003.0008 ◽

2020 ◽

pp. 64-70

Author(s):

Koichi Hirabayashi ◽

Gianpietro Dotti ◽

Barbara Savoldo

Keyword(s):

Clinical Trials ◽

Stem Cell ◽

Cancer Immunotherapy ◽

Immune Cells ◽

Haematopoietic Stem Cell Transplantation ◽

Bispecific Antibodies ◽

Haematopoietic Stem Cell ◽

Cellular Immunotherapy ◽

Tumour Associated Antigens ◽

Inhibitory Molecules

This chapter discusses the principle of cancer immunotherapy in children and adolescents, starting with the most common form of cellular immunotherapy: allogeneic haematopoietic stem-cell transplantation (HSCT). It then discusses specific immunotherapy strategies based on the administration of classic monoclonal antibodies (mAbs) targeting tumour-associated antigens, novel bispecific antibodies that simultaneously target tumour-associated antigens and activate CD3+ T lymphocytes, and mAbs that block key inhibitory molecules of the immune system (checkpoint blockade). Finally, the chapter describes specific cellular immunotherapy approaches, such as tumour vaccine and adoptive transfer of immune cells. Although only a few immunotherapies have so far been incorporated into the standard practice for paediatric cancers, their role is enjoying a new revival, after the promising results obtained in recent clinical trials.

Download Full-text